The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.

Abstract

OBJECTIVE:

Long-term survival for advanced stages of mycosis fungoides (MF) may be beneficially affected by the use of multimodality therapy. We aim to evaluate the activity of vorinostat in combination with interferon (IFN) alpha and extracorporeal photopheresis (ECP) with persistent, progressive advanced stage MF and Sezary syndrome (SS).

PATIENTS AND METHODS:

Three patients with stage IIB-IVA MF/SS were treated with vorinostat 400 mg/day/po. Vorinostat was added to ongoing ECP and IFN-alpha-2a therapies in all three patients.

RESULTS:

The patient with stage IIB MF achieved a complete response. The patient with SS showed a stable disease of less than 50 percent improvement in body surface area with reduction in the sizes of axillary and inguinal lymph nodes. A partial remission was maintained for 24 weeks in the patient with stage IVA MF, followed by rapid disease progression under treatment which led to cessation of vorinostat treatment due to study criteria as well as serious side effects.

CONCLUSION:

Our experience in this case series is suggestive of the synergistic effect of vorinostat in combination with IFN and ECP and supports the efficacy of vorinostat in inducing prolonged responses in patients with progressive disease and/or stable disease in otherwise progressive and treatment refractory late stage MF/SS.

• Authors: Hatice Sanli, Bengu Nisa Akay, Rana Anadolu, Muhit Ozcan, Secil Saral, Aynur Akyol
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 10 Issue 4 Pg. 403-8 (Apr 2011) ISSN: 1545-9616 [Print] United States
• PMID: 21455551 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Histone Deacetylase Inhibitors
• Hydroxamic Acids
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Vorinostat

Topics

• Adult
• Antineoplastic Agents (adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Disease Progression
• Female
• Histone Deacetylase Inhibitors (adverse effects, therapeutic use)
• Humans
• Hydroxamic Acids (adverse effects, therapeutic use)
• Interferon alpha-2
• Interferon-alpha (adverse effects, therapeutic use)
• Male
• Middle Aged
• Mycosis Fungoides (drug therapy, pathology)
• Photopheresis
• Recombinant Proteins
• Severity of Illness Index
• Sezary Syndrome (drug therapy, pathology)
• Treatment Outcome
• Vorinostat